| Q38778226 | A Histologic Basis for the Efficacy of SBRT to the lung |
| Q90296646 | A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients |
| Q38790915 | A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer |
| Q64964699 | Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function. |
| Q38685007 | Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy. |
| Q35796322 | Definitive Treatment of Early-Stage Non-Small Cell Lung Cancer with Stereotactic Ablative Body Radiotherapy in a Community Cancer Center Setting |
| Q33837224 | Dosimetric evaluation of synthetic CT for magnetic resonance-only based radiotherapy planning of lung cancer |
| Q57058757 | Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702) |
| Q37672027 | Guideline for radiotherapy with curative intent in patients with early-stage medically inoperable non-small-cell lung cancer. |
| Q89354934 | Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy |
| Q42514040 | Hypofractionated radiation therapy for basal and squamous cell skin cancer: A meta-analysis |
| Q92545461 | MR-guidance in clinical reality: current treatment challenges and future perspectives |
| Q55073985 | Particle therapy in non-small cell lung cancer. |
| Q90505429 | Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms |
| Q37367501 | Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules |
| Q36363955 | Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy |
| Q37458027 | Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer |
| Q38685466 | Radiobiology of stereotactic body radiation therapy (SBRT). |
| Q33438236 | Splenic irradiation for splenomegaly: A systematic review |
| Q92018403 | Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure |
| Q35824255 | Stereotactic radiotherapy for early stage non-small cell lung cancer |
| Q38409012 | Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea |
| Q52585109 | The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study. |
| Q37178916 | The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy |
| Q100750042 | Upregulation of KCNQ1OT1 promotes resistance to stereotactic body radiotherapy in lung adenocarcinoma by inducing ATG5/ATG12-mediated autophagy via miR-372-3p |